Fermenta Biotech Limited submitted a press release to the stock exchanges containing its unaudited consolidated financial results for the half year ended September 30, 2026 (H1FY27).

Financial Performance Highlights

  • Consolidated Revenue: INR 261.9 crore for H1FY27, representing a 7% decline year-over-year (YoY) from H1FY26.
  • Consolidated EBITDA: INR 45.6 crore for H1FY27, down 34% YoY.
  • Profit After Tax (PAT): INR 18.9 crore for H1FY27, down 52% YoY.
  • Earnings Per Share (Diluted): Rs. 6.67 for H1FY27.

Quarterly Performance (Q2FY27)

  • Revenue: INR 135.8 crore (up 0.1% YoY, up 8% quarter-over-quarter)
  • EBITDA: INR 23.2 crore (down 28% YoY, up 3% QoQ)
  • PAT: INR 9.4 crore (down 48% YoY, down 1% QoQ)
  • EPS (Diluted): Rs. 3.34

Segment-Wise Revenue Breakdown (H1FY27 vs H1FY26)

Nutrition Business:

  • Vitamin D3 – Human Nutrition: INR 162.5 crore (up 2% YoY)
  • Vitamin D3 – Animal Nutrition: INR 22.1 crore (down 52% YoY)
  • Others: INR 24.0 crore (up 58% YoY)

Other Business:

  • Other APIs and Intermediates: INR 22.5 crore (down 1% YoY)
  • Green Chemistry Solutions/Enzymes: INR 3.2 crore (down 8% YoY)
  • Environmental Solutions: INR 16.6 crore (up 10% YoY)
  • Other Income: INR 11.0 crore (down 37% YoY)

Value Unlocking:

  • Real Estate: INR 0 crore (down from INR 1.6 crore in H1FY26)

Operational and Strategic Highlights

  • Human Nutrition Segment: Grew by 2% YoY despite a 13% reduction in volumes. Its contribution to overall revenue increased to nearly two-thirds.
  • Animal Nutrition Segment: Volumes declined 31% YoY, with average realizations down 35% YoY. The company stated it did not pursue sales volumes due to low prices.
  • Geographical Revenue Mix (ex-real estate): India became the largest market at 51% of revenue (up from 40% in H1FY26). Europe contributed 21% (down from 29%), North America 9% (down from 13%), and Others 18% (flat).
  • Subsidiary Performance:
  • German subsidiary: Revenue of INR 13.1 crore (down 62% YoY), EBITDA loss of INR 2.5 crore (down from a profit of INR 7.8 crore YoY).
  • US trading subsidiary: Revenue of INR 17.2 crore (down 43% YoY), EBITDA loss of INR 1.0 crore (down by INR 0.9 crore YoY).
  • Environment subsidiary: Revenue of INR 16.7 crore, EBITDA loss of INR 4.7 crore (down by INR 2.0 crore YoY).
  • Other Income: Was INR 7.5 crore against INR 14.2 crore a year earlier. The decline is attributed to a non-recurring insurance claim of INR 2.7 crore and higher foreign exchange gains in the base period (H1FY26).
  • Product Development & Approvals: VITADEE Green® (plant-source Vitamin D3) received FSSAI approval on July 6, 2026, for use in health supplements, nutraceuticals, and food products.
  • Listing: The company listed on the National Stock Exchange (NSE) on August 4, 2026.

Management Commentary

Prashant Nagre, Managing Director, commented on the results, highlighting the strategic shift towards Human Nutrition and the Indian market. He noted that capacities for VITADEE Green® are expected to be available from Q2FY28 and that the Vitamin D3 analog product Calcifediol is expected to be ready for regulatory approvals by the end of FY27. He also emphasized that the NSE listing has broadened investor access.